These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29113708)

  • 61. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Karagiannis T; Malandris K; Liakos A; Mainou M; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2019 Jan; 21(1):188-193. PubMed ID: 30058208
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The cardiovascular safety of incretin-based therapies: a review of the evidence.
    Petrie JR
    Cardiovasc Diabetol; 2013 Sep; 12():130. PubMed ID: 24011363
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
    Edwards CM
    Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
    [No Abstract]   [Full Text] [Related]  

  • 70. Incretins: what is known, new and controversial in 2013?
    Burcelin R; Thorens B;
    Diabetes Metab; 2013 Apr; 39(2):89-93. PubMed ID: 23523140
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.
    Guo X; Sang C; Tang R; Jiang C; Li S; Liu N; Long D; Du X; Dong J; Ma C
    Diabetes Obes Metab; 2023 Apr; 25 Suppl 1():53-63. PubMed ID: 36864658
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
    Burgmaier M; Heinrich C; Marx N
    Diabet Med; 2013 Mar; 30(3):289-99. PubMed ID: 22804451
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
    Monami M; Zannoni S; Pala L; Silverii A; Andreozzi F; Sesti G; Mannucci E
    Int J Cardiol; 2017 Aug; 240():414-421. PubMed ID: 28501352
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 78. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
    Liu Y; Tian Q; Yang J; Wang H; Hong T
    Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.
    Herzlinger S; Horton ES
    Diabetes Res Clin Pract; 2013 Apr; 100(1):1-10. PubMed ID: 23332049
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.